analyses < analysis < analytical

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 138.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000016 (2009)	Mao Mao An [République populaire de Chine] ; Zui Zou [République populaire de Chine] ; Hui Shen [République populaire de Chine] ; Jun Dong Zhang [République populaire de Chine] ; Yong Bing Cao [République populaire de Chine] ; Yuan Ying Jiang [République populaire de Chine]	The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
000021 (2010)	Nicolas Frey [Suisse] ; Susan Grange [Suisse] ; Thasia Woodworth [Royaume-Uni]	Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
000026 (2016)	Young Ho Lee [Corée du Sud] ; Sang-Cheol Bae [Corée du Sud]	Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta‐analysis of randomized controlled trials
000029 (2011)	Satoru Shinriki [Japon] ; Hirofumi Jono [Japon] ; Mitsuharu Ueda [Japon] ; Kazutoshi Ota [Japon] ; Tomoko Ota [Japon] ; Takanao Sueyoshi [Japon] ; Yuichi Oike [Japon] ; Mutsuko Ibusuki [Japon] ; Akimitsu Hiraki [Japon] ; Hideki Nakayama [Japon] ; Masanori Shinohara [Japon] ; Yukio Ando [Japon]	Interleukin‐6 signalling regulates vascular endothelial growth factor‐C synthesis and lymphangiogenesis in human oral squamous cell carcinoma
000050 (2011)	Masaaki Hiura [Japon] ; Shintaro Abe ; Akinari Tabaru ; Shohei Shimajiri ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Masaru Harada	Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis
000051 (2008)	Atsushi Taga [Japon] ; Soichiro Kita ; Kaori Nishiura [Japon] ; Tomonori Hayashi [Japon] ; Mitsuhiro Kinoshita ; Atsushi Sato [Japon] ; Kentaro Suzuki [Japon] ; Shuji Kodama [Japon] ; Kazuaki Kakehi	Analysis of an antibody pharmaceutical, tocilizumab, by capillary electrophoresis using a carboxylated capillary
000052 (2009)	Miho Suzuki [Japon] ; Misato Hashizume [Japon] ; Hiroto Yoshida [Japon] ; Masahiko Mihara [Japon]	Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule
000066 (2013)	Kanae Tani [Japon] ; Risa Takayanagi [Japon] ; Haruko Yokoyama [Japon] ; Yasuhiko Yamada [Japon]	Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy
000069 (2016)	Nozomu Yanaihara [Japon] ; Yukihiro Hirata [Japon] ; Noriko Yamaguchi [Japon] ; Yukiko Noguchi [Japon] ; Misato Saito [Japon] ; Chie Nagata [Japon] ; Satoshi Takakura [Japon] ; Kyosuke Yamada [Japon] ; Aikou Okamoto [Japon]	Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary
000083 (2012)	Yasuhiko Hirabayashi [Japon] ; Tomonori Ishii [Japon]	The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
000087 (2011)	K. Krüger [Allemagne] ; B. Hellmich [Allemagne] ; A. Rubbert-Roth [Allemagne] ; U. Müller-Ladner [Allemagne] ; A. Kielhorn [Allemagne]	Ist der Vergleich verschiedener Studien zur Wirksamkeit von Biologika bei Patienten mit rheumatoider Arthritis möglich?
000088 (2011)	Emily Beth Devine [États-Unis] ; Rafael Alfonso-Cristancho [États-Unis] ; Sean D. Sullivan [États-Unis]	Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach
000105 (2012)	M. Gallego-Galisteo ; A. Villa-Rubio ; E. Alegre-Del Rey [Espagne] ; E. Márquez-Fernández ; J. J. Ramos-Báez	Indirect comparison of biological treatments in refractory rheumatoid arthritis
000130 (2007)	Gerald Gartlehner [Autriche, États-Unis] ; Richard A. Hansen [États-Unis] ; Beth L. Jonas [États-Unis] ; Patricia Thieda [États-Unis] ; Kathleen N. Lohr [États-Unis]	Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence
000137 (2011)		Adverse effects of biologics: a network meta‐analysis and Cochrane overview
000145 (2012)	I. Demin [Suisse] ; B. Hamrén [Suisse] ; O. Luttringer [Suisse] ; G. Pillai [Suisse] ; T. Jung [Suisse]	Longitudinal Model‐Based Meta‐Analysis in Rheumatoid Arthritis: An Application Toward Model‐Based Drug Development
000187 (2016)	Yehong Wang [États-Unis] ; Rui Zhu [États-Unis] ; Jim Xiao [États-Unis] ; John C. Davis Jr [États-Unis] ; Jaap W. Mandema [États-Unis] ; Jin Y. Jin [États-Unis] ; Meina T. Tang [États-Unis]	Short‐Term Efficacy Reliably Predicts Long‐Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model‐Based Meta‐Analysis
000189 (2013)	Diogo Mendes [Portugal] ; Carlos Alves [Portugal] ; Francisco Batel Marques [Portugal]	Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events
000223 (2010)	J. Möller [Allemagne] ; H. J. Girschick [Allemagne] ; G. Hahn [Allemagne] ; F. Pessler [Allemagne]	Kortikosteroid-induzierte spinale epidurale Lipomatose bei pädiatrischen Patienten
000256 (2012)	Tsuyoshi Kasama [Japon] ; Hidekazu Furuya [Japon] ; Ryo Yanai [Japon] ; Kumiko Ohtsuka [Japon] ; Ryo Takahashi [Japon] ; Nobuyuki Yajima [Japon] ; Yusuke Miwa [Japon] ; Kazuo Kobayashi [Japon]	Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome
000304 (2013)	Tomokazu Nagao ; Reina Kusunoki ; Chiaki Iwamura ; Shigeto Kobayashi ; Wako Yumura ; Yosuke Kameoka [Japon] ; Toshinori Nakayama ; Kazuo Suzuki [Japon]	Correlation of interleukin‐6 and monocyte chemotactic protein‐1 concentrations with crescent formation and myeloperoxidase‐specific anti‐neutrophil cytoplasmic antibody titer in SCG/Kj mice by treatment with anti‐interleukin‐6 receptor antibody or mizoribine

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "analysis" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "analysis" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    analysis
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021